Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 3
A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab pro…
Von Willebrand Disease, Type 3
Estimated
~$10 – $7,500
Hoffmann-La RocheNCT06998524
Phase 1
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous b…
Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia
Estimated
~$10 – $7,500
Bleeding and Clotting Disorders Institute Peoria, IllinoisNCT05500807